ERBB2 and breast cancer: Compared to women who received upfront surgery, women treated with NAC were younger (median age 55.2 vs 50.1 years) and more likely to have stage III BC (34.8% vs 81.5%), ER/PR negative BC (20.7% vs 27.9%) and HER2 positive BC (24.2% vs 33.1%).